Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mostly covered calls.
TDA offers a very esoteric options trading menu, including vertical and calendar put and call spreads. I generally give purchasing preference to a stock that a) trades options b) pays a dividend. To reduce angst, it should trade weekly options. AAPL is ideal for this, and I increase my odds by only trading on a Wednesday, so you basically have a two and a half day exposure.
No, the post is accurate. https://www.bop.gov/inmateloc/
It's just that he conviently left off the middle initial Z.
Like Michael Jordan the basketballer, while the actor is Michael B. Jordan.
Was there any particular reason you did not use the Middle initial "Z"
Was it because that turns up
0 Results for search Nader Z Pourhassan
If you have a Roku device, you add Pluto TV, and it is one of the stations in the News section.
I wrote this to a friend last Monday -
I see doom and gloom for another venerable banking company with 4.1 Billion shares outstanding. Wells Fargo Co (WFC) the Fed recently curtailed their exuberance at paying an increased dividend, and last week they announced a 10,000 job cut. I suspect it will be at least twice that.
Then we see this -
Wells Fargo has more than $1 trillion of VIE assets, about which we currently know very little, because reporting requirements are opaque.
There is going to be a lot of grief to share around.
Needless to say, I am not a fan of any financial stock.
Indeed, that is a whole lot more than India's 1.98
You have something against Bulgarians ?
Mr. Naydenov has been a Director of CytoDyn since June 2009. For more than 20 years, Mr. Naydenov has been actively involved in innovative developments in a variety of fields, ranging from sports, fitness, & health to robotic technology. Since 2001, Mr. Naydenov has served as the Vice President and Director of Milara Incorporated, a leading and multi-faceted company that specializes in wafer-handling robotics, semiconductor systems, and surface mount technologies. In 2006, Mr. Naydenov became the Treasurer of Milara Inc., and additionally began serving as the Director of Milara International, the international representative of Diamond and Equipe brands of Semiconductor Robotics & Systems. Since then, Mr. Naydenov has expanded his experience in innovative developments and industries, with his most recent endeavor beginning in 2017 as the founder of the natural health care product company, Pure Care Pro LLC.
http://www.milarasmt.com
You are correct, it is old. So perhaps July 17 from Johns Hopkins is more appropriate - 1.89 per 100,000 so that's say 19 per million.
https://coronavirus.jhu.edu/data/mortality
Don't think India will need it, they are not in the top 10 for deaths per 100,000. As a matter of fact Mexico is at No. 9 with 17.90 per 100,000, while India's 17 per deaths is per Million.
https://www.statista.com/chart/21170/coronavirus-death-rate-worldwide/
Most interesting about Gilead, Donald Rumsfeld (later 21st Secretary of Defense) was a director from 1988, and served as Chairman from January 1997 to January 2001.
There were 2 responses both saying no monotherapy subject had contracted Covd 19.
Found on another message board site.
Re: Interim Analysis - Jack
I've been involved in a couple of clinical trials and Luckjack has the interim analysis basically right. The company and clinical investigators are not unblinded. If they were it would end the trial. Only the DSMB is unblind to the results and they communicate with the company only in a few written yes/no responses (a faxed single sheet of paper with boxes checked in the trials I was involved with).
There is usually a futility analysis made by the DSMB and getting past that means something. That is, the DSMB looks at the results and their statistician makes a determination of whether the trial could possibly meet its endpoints with statistical significance if allowed to continue. For example, if a trial were half way done and there was no or very minimal separation between the treatment and control groups, then the statistics might show the trial could not possibly meet its endpoints. The company would be told that (Is it futile? yes/no) and in every case I know of that would cause the company to end the trial. So what we know is that that did not happen.
Liver transplant patient.
And it seems that Cheval Holdings owns 69 million shares of it.
https://whalewisdom.com/filer/cheval-holdings-ltd
Sarah Gray Wright passed away.
https://www.bbc.com/news/uk-england-kent-52836125
Agree 100% with you. It is also on his website.
https://drmalcolmkendrick.org/2020/07/05/distorting-science-in-the-covid-pandemic/
I would not be surprised if the FDA pulled an AMARIN on them and said o.k. lets wait on the 390 trial.
How much can CYDY match in political contributions against BP.
The question that needs to be asked, is - Does the agreement give Vyera the right to price leronlimab ?
As you may know, Vyera was the vehicle of Martin Shkreli, who is well known for raising the price of drugs under his control.
Vyera is now under the umbrella of Phoenixus.
https://www.thedailybeast.com/martin-shkreli-still-running-his-drug-company-phoenixus-ag-from-behind-bars-report
Martin Shkreli, the disgraced pharmaceutical executive, continues to run his company from prison with the help of a contraband cellphone, The Wall Street Journal reports. Shkreli was sentenced to seven years in prison last year for defrauding investors in his hedge funds and for manipulating the stock of his pharmaceutical company. The company, Phoenixus AG, brought to light the industry-wide practice of hiking up the prices of rare drugs. Shkreli jacked up the price of one HIV drug from $13.50 to $750. The so-called “pharma bro” recently fired his handpicked chief executive over the phone while he was on vacation, according to a source familiar with the exchange.
Shkreli plans to emerge from jail richer than he entered. According to his own calculations, Phoenixus could be worth $3.7 billion by the time he is freed in 2023. For that to happen, Shkreli plans to acquire more rare drugs in various stages of development and invest in ambitious research and development. The incarcerated executive reportedly spends his time reading pharmaceutical research on the inmate computer lab or on his phone.
For a bit of history, wikipedia is a great read.
https://en.wikipedia.org/wiki/Vyera_Pharmaceuticals
Also see-
https://www.bloomberg.com/opinion/articles/2020-01-30/slapping-around-martin-shkreli-won-t-cut-drug-prices
https://www.cnbc.com/2019/04/24/pharma-bro-martin-shkreli-moved-from-prison-after-rule-breaking.html
July 31, $420
The Perilous Development Of A Potential Biologic Blockbuster
https://www.bioprocessonline.com/doc/the-perilous-development-of-a-potential-biologic-blockbuster-0001
There was a mention of $87 million in milestone payments - any idea what that is about ?
Since he's using other peoples money to finance his move into online gaming. That was the part that got to me. Got into LCAHU @$15.54 in the a.m. and got out at $17.00 in the p.m. Not looking at NKLA at all. May take a shot at SHLL. (On a visit to Toronto some years ago, I specifically went to Niagara Falls to see Tesla's statue. He is a hero.)
CytoDyn Bolts Higher On Mexican Approval Chatter
https://insiderfinancial.com/cytodyn-otcmkts-cydy-bolts-higher-on-mexican-approval-chatter/180087/
A possible clinical trial participant.
Suggest you check with your broker. I bought the units yesterday, and when I called TD to have them split into the stock and the warrants, I was told that I would not be able to trade the stock, so I kept the units, and sold after hours, made $7.2K.
What are your thoughts on LCAHW and LCAHU ?
After reading Marjac's post of the Reply Brief, and seeing all those defense references to Mori, Hayashi and Kurabayshi, all I could think of was Kobayshi Maru to the defense.
Basically, today is a non-event.
Squeaked in minutes before the halt, got another 5K @ $24.06
Thought what the heck that's $1 less that my Jan $25 options.
Judging from previous activity, I would not be at all surprised if the shorts got to cover at $26 to $27, i.e. a low orbital flight, not a moon shot.
Broke my No. 1 Ferenghi rule of acquisition - Do not buy a stock in both IRA and Trading account.
2019-11-14 13F PERCEPTIVE ADVISORS LLC 7,636,079 115,763,
Under what name(s) are these shares held ?